

# Yao Lu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4034152/publications.pdf>

Version: 2024-02-01

24  
papers

298  
citations

1040018

9  
h-index

1058452

14  
g-index

29  
all docs

29  
docs citations

29  
times ranked

247  
citing authors

#	ARTICLE	IF	CITATIONS
1	A New Tool for Rapid Assessment of Acute Exercise-Induced Fatigue. <i>Frontiers in Human Neuroscience</i> , 2022, 16, 856432.	2.0	3
2	Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients. <i>Virologica Sinica</i> , 2022, 37, 390-397.	3.0	10
3	Hepatitis B core-related antigen serum levels are associated with significant liver fibrosis in treatment-naïve chronic HBV infection patients. <i>Journal of Viral Hepatitis</i> , 2022, 29, 438-446.	2.0	1
4	Transient cardioprotective effects of remote ischemic postconditioning on non-reperfused myocardial infarction: longitudinal evaluation study in pigs. <i>International Journal of Cardiology</i> , 2022, 355, 37-43.	1.7	2
5	Dynamic Changes of Cytokine Profiles and Virological Markers Associated With HBsAg Loss During Peginterferon Alpha-2a Treatment in HBeAg-Positive Chronic Hepatitis B Patients. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	10
6	Early Serum HBsAg Kinetics as Predictor of HBsAg Loss in Patients with HBeAg-Negative Chronic Hepatitis B after Treatment with Pegylated Interferon-2a. <i>Virologica Sinica</i> , 2021, 36, 311-320.	3.0	17
7	The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir Therapy. <i>BioMed Research International</i> , 2021, 2021, 1-14.	1.9	11
8	Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens. <i>Liver International</i> , 2021, 41, 1498-1508.	3.9	24
9	ABCA1-Labeled Exosomes in Serum Contain Higher MicroRNA-193b Levels in Alzheimer's Disease. <i>BioMed Research International</i> , 2021, 2021, 1-10.	1.9	14
10	Transforming growth factor $\beta^2$ as a possible independent factor in chronic hepatitis B. <i>Archives of Virology</i> , 2021, 166, 1853-1858.	2.1	4
11	Changes in the Cytokine Profiles of Patients with Chronic Hepatitis B during Antiviral Therapy. <i>Biomedical and Environmental Sciences</i> , 2021, 34, 443-453.	0.2	9
12	Association of cytokines with hepatitis B virus and its antigen. <i>Journal of Medical Virology</i> , 2020, 92, 3426-3435.	5.0	12
13	The reduction in CD8+PD-1+ T cells in liver histological tissue is related to Pegylated IFN- $\alpha$ therapy outcomes in chronic hepatitis B patients. <i>BMC Infectious Diseases</i> , 2020, 20, 590.	2.9	4
14	Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon- $\alpha$ -based therapy. <i>Journal of Viral Hepatitis</i> , 2019, 26, 32-41.	2.0	27
15	Evaluation of a logistic regression model for predicting liver necroinflammation in hepatitis B e antigen-negative chronic hepatitis B patients with normal and minimally increased alanine aminotransferase levels. <i>Journal of Viral Hepatitis</i> , 2019, 26, 42-49.	2.0	17
16	Changes in APRI and FIB-4 in HBeAg-negative treatment-naïve chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy. <i>Clinical and Experimental Medicine</i> , 2019, 19, 309-320.	3.6	12
17	Association of Cytokines with Alanine Aminotransferase, Hepatitis B Virus Surface Antigen and Hepatitis B Envelope Antigen Levels in Chronic Hepatitis B. <i>Chinese Medical Journal</i> , 2018, 131, 1813-1818.	2.3	14
18	Plasmacytoid Dendritic Cell Function and Cytokine Network Profiles in Patients with Acute or Chronic Hepatitis B Virus Infection. <i>Chinese Medical Journal</i> , 2018, 131, 43-49.	2.3	10

#	ARTICLE	IF	CITATIONS
19	Quantitation of Plasmacytoid Dendritic Cells in Chronic Hepatitis B Patients with HBeAg Positivity During PEG-IFN and Entecavir Therapy. <i>Journal of Interferon and Cytokine Research</i> , 2018, 38, 197-205.	1.2	14
20	Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment. <i>Chinese Medical Journal</i> , 2017, 130, 559-565.	2.3	21
21	Negative Correlation of Serum Hepatitis B Surface Antigen and Hepatitis B e Antigen Levels with the Severity of Liver Inflammation in Treatment-naïve Patients with Chronic Hepatitis B Virus Infection. <i>Chinese Medical Journal</i> , 2017, 130, 2697-2702.	2.3	11
22	Ratios of T-helper 2 Cells to T-helper 1 Cells and Cytokine Levels in Patients with Hepatitis B. <i>Chinese Medical Journal</i> , 2017, 130, 1810-1815.	2.3	11
23	The Predictive Value of Baseline HBsAg Level and Early Response for HBsAg Loss in Patients with HBeAg-positive Chronic Hepatitis B during Pegylated Interferon Alpha-2a Treatment. <i>Biomedical and Environmental Sciences</i> , 2017, 30, 177-184.	0.2	15
24	Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a. <i>World Journal of Hepatology</i> , 2016, 8, 637.	2.0	22